(RxWiki News) A new migraine medication is hitting the market.
The US Food and Drug Administration (FDA) has approved Reyvow (lasmiditan) to treat migraines.
Migraines are estimated to affect more than 10 percent of people around the world.
Lasmiditan, available in tablet form, has been approved for adults with migraines with or without aura.
Aura is a sensory phenomenon or visual disturbance. An aura can occur as flashing lights, zig-zag lines or temporary vision loss. Auras typically affect around one-third of people who have migraines.
This medication does not prevent migraines but is an acute treatment.
The approval of Reyvow came after lasmiditan was shown to be effective in two clinical trials.
Common side effects included fatigue and a burning or prickling sensation in the skin. This medication can also cause drowsiness and dizziness.
After taking this medication, it is strongly recommended to wait at least eight hours before driving or operating heavy machinery (even if they feel well enough to do so). If this recommendation cannot be followed, taking Reyvow is not an option.
Furthermore, this medication is not to be taken with alcohol or other medications that depress the central nervous system.
The approval of Reyvow was granted to Eli Lilly and Company.
Speak with your health care provider if you have any questions about migraines.
Written by Anyssa Garza, PharmD, BCMAS